TA-65 and Aging Associated Microvascular Dysfunction
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 180
- 主要终点
- Nitric Oxide Mediated Endothelium-Dependent Vasodilation via Laser Doppler Flowmetry Coupled with Intradermal Microdialysis
研究概览
简要总结
The goal of this clinical trial is to test whether activation of telomerase with a dietary supplement (TA-65) improves microvascular function.
详细描述
The purpose of this clinical trial is to examine whether activation of autophagy with TA-65 which activates telomerase, improves microvascular function and blood pressure in an older population
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- Double (Participant, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy Adults 18 - 35 and 65+ years of age
- •Subjects with clinical diagnosis of CAD
排除标准
- •will include:
- •36-64 years of age without clinical diagnosis of CAD
- •Self-reported habitual vigorous exercise (>20 min, 3 times per week, 1 yr)
- •Major Adverse Cardiovascular Event (MACE) in the last year (heart attack, stroke)
- •Heart Failure
- •Renal Impairment
- •>3 Pre-existing Cardiovascular Risk Factors (healthy groups only)
- •Type 1 or type 2 diabetes
- •Uncontrolled hypertension
- •Current tobacco use or within last 6 months
- •BMI > 35
- •Hyperlipidemia
- •Hypercholesterolemia
- •Use of anti-coagulant drugs
- •Use of anti-platelet drugs
- •Erectile dysfunction medication in the past 6 months
- •Use of topical/non-topical steroids in last 6 months
- •Hormone replacement therapy (Post-Menopause or Gender Reassignment)
- •History of retinopathy
- •Documented neuromuscular disorders
- •Porphyria Cutanea Tarda (blistering of skin to sun; photosensitivity)
- •Pregnancy (young female subjects)
- •Allergy to lidocaine
- •Current diagnosis of cancer with or without active anti-cancer treatment (pharmaceuticals) or treatment within last 12 months
- •Active COVID-19 or within the past 3 months
研究组 & 干预措施
TA-65
TA-65 (250 U) taken once per day
干预措施: TA-65 (Dietary Supplement)
Placebo
Placebo taken once per day
干预措施: Placebo (Other)
结局指标
主要结局
Nitric Oxide Mediated Endothelium-Dependent Vasodilation via Laser Doppler Flowmetry Coupled with Intradermal Microdialysis
时间窗: 28 days
Cutaneous microvascular function measured via laser Doppler flowmetry coupled with intradermal microdialysis of non-specific nitric oxide synthase inhibitor, L-NAME
次要结局
- Systemic Blood Pressure(28 days)
研究者
William Hughes
Postdoc Fellow
Medical College of Wisconsin